Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2007

01-09-2007 | Original Paper

Gut Toxicity During Hemopoietic Stem Cell Transplantation May Predict Acute Graft-Versus-Host Disease Severity in Patients

Authors: Jan-Erik Johansson, Tor Ekman

Published in: Digestive Diseases and Sciences | Issue 9/2007

Login to get access

Abstract

Graft-versus-host disease (GVHD) is the primary complication of allogeneic, hemopoietic, stem cell transplantation (HSCT). Murine models suggest that gut toxicity, induced by the intensive chemotherapy preceding hematopoietic stem cell infusion, aggravates systemic GVHD. In HSCT patients gut toxicity correlates with chemotherapy intensity. The present study investigates acute GVHD severity and intestinal toxicity in patients undergoing allogeneic HSCT. In 38 patients intestinal permeability was assessed before and after chemotherapy (on days −1, +4, +7 and +14 as related to the stem cell infusion). Cumulative acute GVHD (days 0–100) and clinical intestinal toxicity (days 0–14) were evaluated in parallel. Patients with mild, acute GVHD (grades 0–I) had better-preserved intestinal barrier function (P=0.04) and less pronounced cumulative clinical intestinal toxicity (P=0.02) compared with patients with more severe acute GVHD (grades II–IV). Gut toxicity predicts acute GVHD severity. Therefore, gut protective strategies may diminish GVHD severity in allogeneic HSCT patients.
Literature
1.
go back to reference Fegan C, Poynton CH, Whittaker JA (1990) The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 5(6):373–377PubMed Fegan C, Poynton CH, Whittaker JA (1990) The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 5(6):373–377PubMed
2.
go back to reference Johansson JE, Ekman T (1997) Gastrointestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 19(9):921–925PubMedCrossRef Johansson JE, Ekman T (1997) Gastrointestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 19(9):921–925PubMedCrossRef
3.
go back to reference Berg R (1983) Bacterial translocation from the gastrointestinal tract of mice receiving immunosuppressive chemotherapeutic agents. Curr Microbiol 8:285–292CrossRef Berg R (1983) Bacterial translocation from the gastrointestinal tract of mice receiving immunosuppressive chemotherapeutic agents. Curr Microbiol 8:285–292CrossRef
4.
go back to reference Przepiorka D, Weisdorf D, Martin P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl 15(6):825–828 Przepiorka D, Weisdorf D, Martin P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl 15(6):825–828
5.
go back to reference Holler E, Kolb HJ, Mittermuller J, et al. (1995) Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86(3):890–899PubMed Holler E, Kolb HJ, Mittermuller J, et al. (1995) Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86(3):890–899PubMed
6.
go back to reference Holler E, Kolb HJ, Moller A, et al. (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75(4):1011–1016 [see comments]PubMed Holler E, Kolb HJ, Moller A, et al. (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75(4):1011–1016 [see comments]PubMed
7.
go back to reference Antin JH, Weinstein HJ, Guinan EC, et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84(4):1342–1348PubMed Antin JH, Weinstein HJ, Guinan EC, et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84(4):1342–1348PubMed
8.
go back to reference Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83(8):2360–2367PubMed Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83(8):2360–2367PubMed
9.
go back to reference Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8):3204–3213PubMed Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8):3204–3213PubMed
10.
go back to reference Hill GR, Teshima T, Gerbitz A, et al. (1999) Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104(4):459–467PubMedCrossRef Hill GR, Teshima T, Gerbitz A, et al. (1999) Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104(4):459–467PubMedCrossRef
11.
go back to reference Nestel FP, Price KS, Seemayer TA, Lapp WS (1992) Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175(2):405–413PubMedCrossRef Nestel FP, Price KS, Seemayer TA, Lapp WS (1992) Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175(2):405–413PubMedCrossRef
12.
go back to reference Storb R, Prentice RL, Buckner CD, et al. (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308(6):302–307PubMedCrossRef Storb R, Prentice RL, Buckner CD, et al. (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308(6):302–307PubMedCrossRef
13.
go back to reference Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR (1998) Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92(10):3960–3967PubMed Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR (1998) Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92(10):3960–3967PubMed
14.
go back to reference Hill GR, Cooke KR, Teshima T, et al. (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102(1):115–123PubMed Hill GR, Cooke KR, Teshima T, et al. (1998) Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102(1):115–123PubMed
15.
go back to reference Slavin S, Nagler A, Naparstek E, et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756–763PubMed Slavin S, Nagler A, Naparstek E, et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756–763PubMed
16.
go back to reference Adkins D, Brown R, Khoury H, et al. (1998) Low-intensity conditioning regimen for related donor allogeneic peripheral blood stem cell (PBSC) transplant using low-dose (550 cGy) high dose rate (30 cGy/min) single-exposure total body irradiation (TBI). Blood 92(10):138a Adkins D, Brown R, Khoury H, et al. (1998) Low-intensity conditioning regimen for related donor allogeneic peripheral blood stem cell (PBSC) transplant using low-dose (550 cGy) high dose rate (30 cGy/min) single-exposure total body irradiation (TBI). Blood 92(10):138a
17.
go back to reference Johansson JE, Brune M, Ekman T (2001) The gut mucosa barrier is preserved during allogeneic, hemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transpl 28(8):737–742CrossRef Johansson JE, Brune M, Ekman T (2001) The gut mucosa barrier is preserved during allogeneic, hemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transpl 28(8):737–742CrossRef
18.
go back to reference Bjarnason I, O’Morain C, Levi AJ, Peters TJ (1983) Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 85(2):318–322PubMed Bjarnason I, O’Morain C, Levi AJ, Peters TJ (1983) Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 85(2):318–322PubMed
19.
go back to reference Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214PubMedCrossRef Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214PubMedCrossRef
20.
go back to reference Lehnert S, Rybka WB, Seemayer TA (1986) Amplification of the graft-versus-host reaction by partial body irradiation. Transplantation 41(6):675–679PubMedCrossRef Lehnert S, Rybka WB, Seemayer TA (1986) Amplification of the graft-versus-host reaction by partial body irradiation. Transplantation 41(6):675–679PubMedCrossRef
21.
go back to reference Lehnert S, Rybka WB (1994) Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transpl 13(4):473–477 Lehnert S, Rybka WB (1994) Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transpl 13(4):473–477
22.
go back to reference Sykes M, Eisenthal A, Sachs DH (1988) Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 140(9):2903–2911PubMed Sykes M, Eisenthal A, Sachs DH (1988) Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 140(9):2903–2911PubMed
Metadata
Title
Gut Toxicity During Hemopoietic Stem Cell Transplantation May Predict Acute Graft-Versus-Host Disease Severity in Patients
Authors
Jan-Erik Johansson
Tor Ekman
Publication date
01-09-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9404-x

Other articles of this Issue 9/2007

Digestive Diseases and Sciences 9/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine